Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of dapagliflozin on anaemia in DAPA‐HF
Kieran F. Docherty, James P. Curtain, Inder S. Anand, et al.
European Journal of Heart Failure (2021) Vol. 23, Iss. 4, pp. 617-628
Open Access | Times Cited: 74

Showing 1-25 of 74 citing articles:

SGLT2 inhibitors: role in protective reprogramming of cardiac nutrient transport and metabolism
Milton Packer
Nature Reviews Cardiology (2023) Vol. 20, Iss. 7, pp. 443-462
Open Access | Times Cited: 102
Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF
Kieran F. Docherty, Paul Welsh, Subodh Verma, et al.
Circulation (2022) Vol. 146, Iss. 13, pp. 980-994
Open Access | Times Cited: 95
Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
Elaine Ku, Lucia Del Vecchio, Kai‐Uwe Eckardt, et al.
Kidney International (2023) Vol. 104, Iss. 4, pp. 655-680
Open Access | Times Cited: 72
Redefining Iron Deficiency in Patients With Chronic Heart Failure
Milton Packer, Stefan D. Anker, Javed Butler, et al.
Circulation (2024) Vol. 150, Iss. 2, pp. 151-161
Open Access | Times Cited: 17
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism
Jun Tang, Lifang Ye, Qiqi Yan, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 59
Potential Interactions When Prescribing SGLT2 Inhibitors and Intravenous Iron in Combination in Heart Failure
Milton Packer
JACC Heart Failure (2022) Vol. 11, Iss. 1, pp. 106-114
Open Access | Times Cited: 50
Heart failure: an update from the last years and a look at the near future
Mauro Riccardi, Antonio Maria Sammartino, Massimo Piepoli, et al.
ESC Heart Failure (2022) Vol. 9, Iss. 6, pp. 3667-3693
Open Access | Times Cited: 49
Effects of empagliflozin on erythropoiesis in heart failure: data from the Empire HF trial
Camilla Fuchs Andersen, Massar Omar, Andreas Glenthøj, et al.
European Journal of Heart Failure (2022) Vol. 25, Iss. 2, pp. 226-234
Open Access | Times Cited: 48
How can sodium–glucose cotransporter 2 inhibitors stimulate erythrocytosis in patients who are iron‐deficient? Implications for understanding iron homeostasis in heart failure
Milton Packer
European Journal of Heart Failure (2022) Vol. 24, Iss. 12, pp. 2287-2296
Open Access | Times Cited: 47
Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction
Arjun Pandey, Deepak L. Bhatt, Avinash Pandey, et al.
European Heart Journal (2023) Vol. 44, Iss. 37, pp. 3640-3651
Closed Access | Times Cited: 38
Real‐world use of sodium–glucose cotransporter 2 inhibitors in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry
Davide Stolfo, Lars H. Lund, Lina Benson, et al.
European Journal of Heart Failure (2023) Vol. 25, Iss. 9, pp. 1648-1658
Open Access | Times Cited: 36
Dapagliflozin and Anemia in Patients with Chronic Kidney Disease
Akihiko Koshino, Meir Schechter, Glenn M. Chertow, et al.
NEJM Evidence (2023) Vol. 2, Iss. 6
Open Access | Times Cited: 34
Empagliflozin effects on iron metabolism as a possible mechanism for improved clinical outcomes in non-diabetic patients with systolic heart failure
Christiane E. Angermann, Carlos G. Santos‐Gallego, Juan Antonio Requena-Ibáñez, et al.
Nature Cardiovascular Research (2023) Vol. 2, Iss. 11, pp. 1032-1043
Open Access | Times Cited: 29
Use of SGLT2 Inhibitors vs GLP-1 RAs and Anemia in Patients With Diabetes and CKD
Jia-Chian Hu, Shih‐Chieh Shao, Daniel Hsiang-Te Tsai, et al.
JAMA Network Open (2024) Vol. 7, Iss. 3, pp. e240946-e240946
Open Access | Times Cited: 13
Intravenous iron and SGLT2 inhibitors in iron‐deficient patients with heart failure and reduced ejection fraction
Kieran F. Docherty, John J.V. McMurray, Paul R. Kalra, et al.
ESC Heart Failure (2024) Vol. 11, Iss. 4, pp. 1875-1879
Open Access | Times Cited: 10
Anemia Management in the Cardiorenal Patient: A Nephrological Perspective
María Marqués, José Pórtoles, Marta Cobo Marcos, et al.
Journal of the American Heart Association (2025) Vol. 14, Iss. 5
Open Access | Times Cited: 1
Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR‐Reduced
João Pedro Ferreira, Stefan D. Anker, Javed Butler, et al.
European Journal of Heart Failure (2021) Vol. 24, Iss. 4, pp. 708-715
Open Access | Times Cited: 54
Empagliflozin in Heart Failure: Regional Nephron Sodium Handling Effects
Veena S. Rao, Juan B. Ivey‐Miranda, Zachary L. Cox, et al.
Journal of the American Society of Nephrology (2023) Vol. 35, Iss. 2, pp. 189-201
Open Access | Times Cited: 20
Mechanistic and Clinical Comparison of the Erythropoietic Effects of SGLT2 Inhibitors and Prolyl Hydroxylase Inhibitors in Patients with Chronic Kidney Disease and Renal Anemia
Milton Packer
American Journal of Nephrology (2023) Vol. 55, Iss. 2, pp. 255-259
Open Access | Times Cited: 19
Cardioprotective Effect of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients: A Multicenter Propensity Score Matched Study
Jeong‐Hoon Lim, Soie Kwon, Yu Jin Seo, et al.
Kidney International Reports (2024) Vol. 9, Iss. 8, pp. 2474-2483
Open Access | Times Cited: 7
Potential Mediators for Treatment Effects of Novel Diabetes Medications on Cardiovascular and Renal Outcomes: A Meta‐Regression Analysis
José M. Rodriguez‐Valadez, Malak Tahsin, Umesh Masharani, et al.
Journal of the American Heart Association (2024) Vol. 13, Iss. 4
Open Access | Times Cited: 6
Evolution of sodium-glucose co-transporter 2 inhibitors from a glucose-lowering drug to a pivotal therapeutic agent for cardio-renal-metabolic syndrome
Hiroki Akiyama, Akihiro Nishimura, Naru Morita, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 16
Is There a Role for SGLT2 Inhibitors in Patients with End-Stage Kidney Disease?
Rehma Siddiqui, Yoshitsugu Obi, Neville R. Dossabhoy, et al.
Current Hypertension Reports (2024) Vol. 26, Iss. 12, pp. 463-474
Open Access | Times Cited: 5
Anaemia predicts iron homoeostasis dysregulation and modulates the response to empagliflozin in heart failure with reduced ejection fraction: the EMPATROPISM-FE trial
Christiane E. Angermann, Susanne Sehner, Louisa M.S. Gerhardt, et al.
European Heart Journal (2024)
Open Access | Times Cited: 5
Cardiovascular effects of non-insulin glucose-lowering agents: a comprehensive review of trial evidence and potential cardioprotective mechanisms
Gianluigi Savarese, Javed Butler, Lars H. Lund, et al.
Cardiovascular Research (2021) Vol. 118, Iss. 10, pp. 2231-2252
Open Access | Times Cited: 32
Page 1 - Next Page

Scroll to top